JPWO2019145509A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019145509A5 JPWO2019145509A5 JP2020560595A JP2020560595A JPWO2019145509A5 JP WO2019145509 A5 JPWO2019145509 A5 JP WO2019145509A5 JP 2020560595 A JP2020560595 A JP 2020560595A JP 2020560595 A JP2020560595 A JP 2020560595A JP WO2019145509 A5 JPWO2019145509 A5 JP WO2019145509A5
- Authority
- JP
- Japan
- Prior art keywords
- cell
- exchange protein
- target
- peptide exchange
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000765 processed proteins & peptides Proteins 0.000 claims 57
- 102000004169 proteins and genes Human genes 0.000 claims 42
- 108090000623 proteins and genes Proteins 0.000 claims 42
- 210000004027 cell Anatomy 0.000 claims 25
- 238000000034 method Methods 0.000 claims 24
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 14
- 102100028976 HLA class I histocompatibility antigen, B alpha chain Human genes 0.000 claims 13
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims 13
- 150000001875 compounds Chemical class 0.000 claims 12
- 230000002163 immunogen Effects 0.000 claims 11
- 210000004962 mammalian cell Anatomy 0.000 claims 9
- 239000012634 fragment Substances 0.000 claims 8
- 230000001717 pathogenic effect Effects 0.000 claims 6
- 210000001744 T-lymphocyte Anatomy 0.000 claims 5
- 239000000427 antigen Substances 0.000 claims 5
- 102000036639 antigens Human genes 0.000 claims 5
- 108091007433 antigens Proteins 0.000 claims 5
- 230000005847 immunogenicity Effects 0.000 claims 5
- 230000002708 enhancing effect Effects 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 238000000338 in vitro Methods 0.000 claims 4
- 244000052769 pathogen Species 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 102100028082 Tapasin Human genes 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 210000004443 dendritic cell Anatomy 0.000 claims 3
- 108020004707 nucleic acids Proteins 0.000 claims 3
- 102000039446 nucleic acids Human genes 0.000 claims 3
- 150000007523 nucleic acids Chemical class 0.000 claims 3
- 230000004936 stimulating effect Effects 0.000 claims 3
- 108010059434 tapasin Proteins 0.000 claims 3
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims 2
- 102000043129 MHC class I family Human genes 0.000 claims 2
- 108091054437 MHC class I family Proteins 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 206010022000 influenza Diseases 0.000 claims 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 1
- 101150064935 HELI gene Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101100449157 Human cytomegalovirus (strain AD169) GO gene Proteins 0.000 claims 1
- 101100371784 Human cytomegalovirus (strain Merlin) UL142 gene Proteins 0.000 claims 1
- 101100449158 Human cytomegalovirus (strain Merlin) UL74 gene Proteins 0.000 claims 1
- 208000022361 Human papillomavirus infectious disease Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 102000005348 Neuraminidase Human genes 0.000 claims 1
- 108010006232 Neuraminidase Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 108010090804 Streptavidin Proteins 0.000 claims 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 claims 1
- 101150111135 UL1 gene Proteins 0.000 claims 1
- 101150087840 UL11 gene Proteins 0.000 claims 1
- 101150042088 UL16 gene Proteins 0.000 claims 1
- 101150099617 UL5 gene Proteins 0.000 claims 1
- 101150081415 UL55 gene Proteins 0.000 claims 1
- 101150026859 UL9 gene Proteins 0.000 claims 1
- 230000003213 activating effect Effects 0.000 claims 1
- 101150029683 gB gene Proteins 0.000 claims 1
- 101150055782 gH gene Proteins 0.000 claims 1
- 101150015940 gL gene Proteins 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000036039 immunity Effects 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 239000003446 ligand Substances 0.000 claims 1
- 239000007787 solid Substances 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023213107A JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1801323.5A GB201801323D0 (en) | 2018-01-26 | 2018-01-26 | Peptide exchange protein |
| GB1801323.5 | 2018-01-26 | ||
| GBGB1813737.2A GB201813737D0 (en) | 2018-08-23 | 2018-08-23 | Peptide exchange protein |
| GB1813737.2 | 2018-08-23 | ||
| PCT/EP2019/051907 WO2019145509A1 (en) | 2018-01-26 | 2019-01-25 | Peptide exchange protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213107A Division JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021515588A JP2021515588A (ja) | 2021-06-24 |
| JP2021515588A5 JP2021515588A5 (https=) | 2022-01-19 |
| JPWO2019145509A5 true JPWO2019145509A5 (https=) | 2022-01-19 |
Family
ID=65234583
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020560595A Pending JP2021515588A (ja) | 2018-01-26 | 2019-01-25 | ペプチド交換蛋白質 |
| JP2023213107A Pending JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023213107A Pending JP2024029012A (ja) | 2018-01-26 | 2023-12-18 | ペプチド交換蛋白質 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12397036B2 (https=) |
| EP (1) | EP3743093A1 (https=) |
| JP (2) | JP2021515588A (https=) |
| CN (1) | CN111836635A (https=) |
| AU (1) | AU2019211121B2 (https=) |
| CA (1) | CA3089154A1 (https=) |
| WO (1) | WO2019145509A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11814420B2 (en) | 2018-07-06 | 2023-11-14 | The Regents Of The University Of California | Peptide deficient-MHC class I/chaperone compositions and methods |
| EP4085069A1 (en) * | 2020-01-03 | 2022-11-09 | The Regents of The University of California | Systems and methods for identification of mhc-i peptide epitopes |
| US12534510B2 (en) | 2020-04-16 | 2026-01-27 | The Regents Of The University Of California | Peptide-receptive MHC-I complex compositions and methods |
| WO2023163980A1 (en) * | 2022-02-22 | 2023-08-31 | The Children's Hospital Of Philadelphia | Systems and methods for chaperone-mediated ligand exchange on mhc-i and mhc-related molecules using chicken tapbpr |
| WO2026024596A1 (en) * | 2024-07-22 | 2026-01-29 | The Children's Hospital Of Philadelphia | Methods of stimulating an immune response |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5541104A (en) | 1991-05-23 | 1996-07-30 | Ludwig Institute For Cancer Research | Monoclonal antibodies which bind to tumor rejection antigen precursor mage-1 |
| US6235525B1 (en) | 1991-05-23 | 2001-05-22 | Ludwig Institute For Cancer Research | Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof |
| US5342774A (en) | 1991-05-23 | 1994-08-30 | Ludwig Institute For Cancer Research | Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1 |
| ES2225824T3 (es) | 1992-08-31 | 2005-03-16 | Ludwig Institute For Cancer Research | Nonapeptido aislado derivado del gen mage-3 y presentado por hla-a1, y sus usos. |
| US6222012B1 (en) | 1992-08-31 | 2001-04-24 | Ludwig Institute For Cancer Research | Isolated nonapeptides presented by HLA molecules, and uses thereof |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| WO1995023874A1 (en) | 1994-03-01 | 1995-09-08 | Ludwig Institute For Cancer Research | Determination of cancerous conditions by mage gene expression |
| US6291430B1 (en) | 1997-09-12 | 2001-09-18 | Ludwig Institute For Cancer Research | Mage-3 peptides presented by HLA class II molecules |
| US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
| US6692923B2 (en) * | 1999-04-14 | 2004-02-17 | Incyte Corporation | Tapasin-like protein |
| AU2001260847A1 (en) | 2000-05-24 | 2001-12-03 | Genesis Research And Development Corporation Limited | Compositions isolated from skin cells and methods for their use |
| US7947436B2 (en) * | 2004-12-13 | 2011-05-24 | Alethia Biotherapeutics Inc. | Polynucleotides and polypeptide sequences involved in the process of bone remodeling |
| JP2011518115A (ja) * | 2008-01-28 | 2011-06-23 | タップイミューン インコーポレイテッド | 免疫応答を増強するためのタパシン増加 |
| US9209965B2 (en) | 2014-01-14 | 2015-12-08 | Microsemi Semiconductor Ulc | Network interface with clock recovery module on line card |
| CN111909278B (zh) | 2014-01-27 | 2024-04-09 | 分子模板公司 | Mhc i类表位递送多肽 |
| CN107857819A (zh) * | 2017-07-03 | 2018-03-30 | 江苏西迪尔生物技术有限公司 | 多功能融合蛋白及其应用 |
| CN112469479B (zh) | 2018-07-10 | 2024-08-13 | 康涅狄格大学 | 治疗癌症和自身免疫性疾病的试剂和方法 |
-
2019
- 2019-01-25 JP JP2020560595A patent/JP2021515588A/ja active Pending
- 2019-01-25 US US16/964,695 patent/US12397036B2/en active Active
- 2019-01-25 EP EP19701859.1A patent/EP3743093A1/en active Pending
- 2019-01-25 CA CA3089154A patent/CA3089154A1/en active Pending
- 2019-01-25 CN CN201980018422.2A patent/CN111836635A/zh not_active Withdrawn
- 2019-01-25 AU AU2019211121A patent/AU2019211121B2/en active Active
- 2019-01-25 WO PCT/EP2019/051907 patent/WO2019145509A1/en not_active Ceased
-
2023
- 2023-12-18 JP JP2023213107A patent/JP2024029012A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6321261B2 (ja) | ワクチン組成物及びその使用方法 | |
| JP2021515588A5 (https=) | ||
| US11896665B2 (en) | Human herpesvirus immunotherapy | |
| JP2021517813A5 (https=) | ||
| Tindle et al. | A vaccine conjugate of ‘ISCAR’immunocarrier and peptide epitopes of the E7 cervical cancer‐associated protein of human papillomavirus type 16 elicits specific Th1‐and Th2‐type responses in immunized mice in the absence of oil‐based adjuvants | |
| La Rosa et al. | Preclinical development of an adjuvant-free peptide vaccine with activity against CMV pp65 in HLA transgenic mice | |
| JP2021517895A5 (https=) | ||
| TW202039587A (zh) | 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位 | |
| US20230355733A1 (en) | APC targeting units for immunotherapy | |
| Fries et al. | HIV envelope antigen valency on peptide nanofibers modulates antibody magnitude and binding breadth | |
| WO2021236513A1 (en) | Vaccine compositions comprising endogenous gag polypeptides | |
| JP7642236B2 (ja) | アプタマーベースのｃａｒ ｔ－細胞スイッチ | |
| JPWO2019145509A5 (https=) | ||
| Melchers et al. | A stabilized HIV-1 envelope glycoprotein trimer fused to CD40 ligand targets and activates dendritic cells | |
| Li et al. | Endogenous capsid-forming protein ARC for self-assembling nanoparticle vaccines | |
| Matsuda et al. | Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice | |
| Baz et al. | Branched and linear lipopeptide vaccines have different effects on primary CD4+ and CD8+ T-cell activation but induce similar tumor-protective memory CD8+ T-cell responses | |
| Xu et al. | Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine | |
| Jung et al. | SARS-CoV-2 vaccine based on ferritin complexes with screened immunogenic sequences from the Fv-antibody library | |
| WO2022238363A1 (en) | Immunogenic constructs and vaccines for use in the prophylactic and therapeutic treatment of infectious diseases | |
| JP7519418B2 (ja) | Ｃｄ４０およびｓｔｉｎｇ経路を活性化する遺伝子アジュバントの発現のためのウイルスベクター構築物 | |
| CN100379853C (zh) | 包含rre和cte的遗传构建体和组合物及其用途 | |
| Nora et al. | Improved Tumor Specificity of Mesothelin (MSLN)-specific Killer Immunoglobulin Receptor (KIR)-based Chimeric Antigen Receptor (CAR) T cell therapy SynKIR-110 3562 | |
| CN119432917A (zh) | 一种靶向外周免疫组织的基因免疫载体及其应用 | |
| Steinbuck et al. | Amphiphile-engineered DNA adjuvants stimulate strong type I IFN production in lymph nodes via cytosolic danger-sensing to induce potent cellular and humoral immunity in mice and non-human primates |